€4m Funding from EU Commission for New Healthcare Innovation to improve the Treatment of Depression
Innovative Oxfordshire based healthcare company P1vital Ltd announces that it has been awarded €4 Million from the EU Commission for further clinical research across Europe of a novel medical device to improve the treatment of depression.
The PReDicT (Predicting Response to Depression Treatment) project received the EU funding under the Horizon 2020 SME Instrument Programme and is one of 44 projects to be successful from 962 proposals received in June 2015.
The objective of the PReDicT project is to conduct clinical, health economic and commercial research to validate the clinical performance and complete the pre-commercial development of the eHealth Emotional Test Battery (eH-ETB), a unique medical device to improve the treatment and management of depression in clinical practice. On completion of the PReDicT project, the eH-ETB will be ready for market launch.
The eH-ETB is the first device of its kind and is a major breakthrough in the treatment of depression. The eH-ETB has the potential to significantly reduce the time for patients’ suffering from this serious illness to return to good mental health.
It can take several months for physicians to identify an effective antidepressant treatment for their patients. The eH-ETB will enable physicians to identify after only 1 week of starting treatment, whether or not an antidepressant is working. This information will significantly reduce the time required to identify an effective treatment and thereby decrease the time to response and remission for depressed patients.
P1vital’s eH-ETB device has been developed using the same technology as a validated clinical trial version that has been used by the pharmaceutical industry in drug development over the last 10 years. P1vital recently demonstrated that this technology could be successfully applied in a healthcare setting through a UK Proof of Concept study (funded by SBRI Healthcare, NHS England) which showed that the eH-ETB after 7-9 days could predict with 78% certainty whether a patient was not going to respond to an antidepressant.
Jonathan Kingslake, Chief Executive Officer of P1vital Products Ltd commented:
“We are delighted with the award and that our innovation in the mental health arena has been recognised and supported by the European Commission.”
“With an estimated 350million people worldwide suffering from depression, the opportunity to improve millions of lives by accelerating patient recovery from depression is very exciting. We look forward to commencing this project which will provide the evidence and the business case to maximise the global adoption of the product across the healthcare sector.”